Editas Medicine
discovery-phase pharmaceutical company
EDIT Nasdaq
ISIN US28106W1036 SEC CIK 1650664 LEI 5299000AON4Q9NT2JE42
Follow Editas Medicine
Weekly email: filings, results
Revenue, last quarter
$10.4M
+37.4% vs same quarter last year
Net income
−$23.4M
+6.9% vs same quarter last year
EPS, diluted
−$0.15
+46.4% vs same quarter last year
Operating cash flow
−$21.2M
+31.3% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $40.5M | −$160.1M |
| FY24 | $32.3M | −$237.1M |
| FY23 | $78.1M | −$153.2M |
| FY22 | $19.7M | −$220.4M |
| FY21 | $25.5M | −$192.5M |
| FY20 | $90.7M | −$116M |
| FY19 | $20.5M | −$133.7M |
| FY18 | $31.9M | −$110M |
| FY17 | $13.7M | −$120.3M |
| FY16 | $6.1M | −$97.2M |
| FY15 | - | −$72.9M |
| FY14 | - | −$13.7M |
| FY13 | - | - |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | −394.9% | −395% |
| FY24 | −777.2% | −733.7% |
| FY23 | −216.6% | −196.1% |
| FY22 | −1146.3% | −1118.3% |
| FY21 | −756.1% | −753.6% |
| FY20 | −148.6% | −127.8% |
| FY19 | −686.4% | −651.4% |
| FY18 | −356.1% | −344.3% |
| FY17 | −873.6% | −876.5% |
| FY16 | −1605.6% | −1605.5% |
| FY15 | - | - |
| FY14 | - | - |
| FY13 | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$165.8M |
| FY24 | −$219.1M |
| FY23 | −$136.9M |
| FY22 | −$181.5M |
| FY21 | −$171.8M |
| FY20 | −$187M |
| FY19 | −$46.8M |
| FY18 | −$50.5M |
| FY17 | −$11.5M |
| FY16 | −$53.7M |
| FY15 | −$6.9M |
| FY14 | −$9.9M |
| FY13 | - |
- Editas Medicine
- Healthcare median
Show the numbers
| Year | Editas Medicine | Healthcare median |
|---|---|---|
| FY25 | −395% | −30.6% |
| FY24 | −733.7% | −47% |
| FY23 | −196.1% | −58% |
| FY22 | −1118.3% | −80.4% |
| FY21 | −753.6% | −71.9% |
| FY20 | −127.8% | −62.2% |
| FY19 | −651.4% | −46.3% |
| FY18 | −344.3% | −49.6% |
| FY17 | −876.5% | −45.9% |
| FY16 | −1605.5% | −36% |
| FY15 | - | −38.4% |
| FY14 | - | −35.5% |
| FY13 | - | −37.1% |